

March 27, 2025

BrightPath to Present the Preclinical Data of iPSC-derived HER2 CAR-iNKT cells at AACR 2025

Tokyo, Japan - March 27, 2025/ -- BrightPath Biotherapeutics (TSE Growth 4954), a clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics, today announced that the Company will present preclinical data on iPSC-derived HER2 CAR-iNKT cells, demonstrating their ability to activate anti-tumor immune cells in vivo, at the American Association for Cancer Research Annual Meeting (AACR 2025, April 25-30, Chicago). Summary of the abstract and the electronic poster will be posted on the website of BrightPath after AACR 2025 is held.

iPSC-derived HER2 CAR-iNKT cells enhance the activity of immune cells against cancer cells.
(Abstract Number 6105)

Date & Time: 2 p.m.-5 p.m. CDT on Tuesday, April 29, 2025

About BrightPath:

BrightPath is a clinical stage biopharmaceutical company focused on the development of novel cancer therapies to transform cancer treatment for refractory or progressive cancers that cannot be treated with conventional standard therapies. BrightPath is actively involved in developing cell therapies, currently in clinical trials, and immunomodulatory antibodies.

For more information, visit www.brightpathbio.com/English/

Investor and Media Contact:

irpr@brightpathbio.com

www.brightpathbio.com/English/